Deputy Minister of Health Tran Van Thuan held an online working session with France’s Xenothera company on cooperation to conduct the third phase of clinical trial of Xenothera-developed XAV-19 COVID-19 treatment drug and the transfer of XAV-19 production technology to Vietnam.
NANTES, France & BOULOGNE-BILLANCOURT, France--(BUSINESS WIRE)--The biotech company XENOTHERA has begun the European clinical trial of its anti-COVID treatment, XAV-19. The Nantes laboratory is the sponsor of the trial, called EUROXAV, which will be carried out by Excelya, a leading European contract research organization (CRO) specializing in clinical research. EUROXAV is a multi-center, double-blind phase III trial that will recruit 722 patients with moderate COVID, hospitalized or monitored remotely. The trial will take place in Greece, Bulgaria, Romania, Spain and Turkey.